Ronald Baker (@bavariaron) profile picture

MBA, Mentor, and Protégé

Joined November 2016
Photo by Ronald Baker (@bavariaron)Photo by Ronald Baker (@bavariaron)Photo by Ronald Baker (@bavariaron)Photo by Ronald Baker (@bavariaron)Photo by Ronald Baker (@bavariaron)Photo by Ronald Baker (@bavariaron)Photo by Ronald Baker (@bavariaron)Photo by Ronald Baker (@bavariaron)Photo by Ronald Baker (@bavariaron)Photo by Ronald Baker (@bavariaron)
Approval 44 Days after CNPV Award!
This Post is from an account that no longer exists. Learn more
1
257
$SGMO $IOVA ** One Pivotal Trial for FDA Approval ** “One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma“ “Confirmative evidence can include mechanistic science, data from a related indication, animal models, information from other drugs of the same class, real-world evidence, or a second adequate and well-controlled study.“ NEJM Concluding paragraph: Going forward, the FDA’s default position is that one adequate and well-controlled study, combined with confirmatory evidence, will serve as the basis of marketing authorization of novel products. The FDA will carefully examine all aspects of study design with particular focus on controls, end points, effect size, and statistical protocols. Without examination of the quality of a study, two trials may even provide a false assurance. The FDA expects a surge in drug development in response to our initiative. nejm.org/doi/full/10.1056/NE…
6
2
29
8,336
** NVO CEO Wished PFE Luck w/ Metsera ** “Our colleagues in Pfizer were able to take those assets for a bit more and we wish them luck,” “I have said a number of times that those assets were worth the price that they had mentioned to us and not a penny more—and I still stand by that,” $VKTX $GPCR fiercebiotech.com/biotech/no…
1
188
This was a prescient post—you called it accurately.
$PFE @AlbertBourla may need to prep for a number of obesity setbacks in 2026 and beyond. To start with Metsera Vesper 3. This is based dose escalation then monthly .. it is clear to me will disappoint big in efficacy. I wonder why $MTSR didn’t push the dose > 1.2 mg but I believe this Halo-tag likely narrows therapeutic window. In phase 1 -2024 Metsera reported SAD of up to 1.6 mg. Only mentioned efficacy of 1.2 mg. And then MAD was gone up to 1.2 mg only. No details of vomit that I could find. In phase 2A they decided to escalate just up to 1.2 mg. Now they are testing monthly 4.8 mg.. will see how it goes. I doubt this will result in serious extra wt loss unless it triggers significant GI issues - Also the oral peptide hype in extreme form. They claim to have started po MEt 002 in Canada in 2024. No outcome reporting and no trace of it on clinical trials .Gov Later claimed to be doing MET 024 that never progressed into humans and then CEO stated starting the same sc 097 in oral form but again no trace on clinical trial .gov Metsera founded in 2022 on assets from a single UK academic lab and did licensing deal with a Korean company for enhancement of oral peptide delivery. No evidence of that system working and any pharma could have licensed it. Oral peptide engineering is speciality of $PTGX and little bit $MRK through macrocyclic approach that is beyond Metsera reach and takes years to optimize and keep the molecules effective I don’t see Pfizer coming any close to $LLy or even $NVO by 2023 based on these mediocre assets.
3
777
$XBI Cantor Rare Disease Webinar Series – Still More to Come
Over the course of February, Cantor plans to host 25+ webinars related tob the #rare #disease will include hearing from Senior Health Policy Advisors KOLs,advocacy groups.organizations, company management Stay tuned for the preliminary agenda next week, with more to come! $SGMO
2
9
2,107
$SGMO ** CNBC Cures: Understanding Rare Disease ** Listen to the discussion at the end of the video—what comes to mind? youtu.be/dlCrLhDewHU?si=meWn…
Mark your calendar! 📅 FDA's virtual #RareDiseaseDay is February 23, 2026. Together, we're prioritizing accelerating medical products for rare diseases and ensuring patient perspectives guide our decisions. Every rare disease matters. Register now: fda.gov/rarediseaseday #FDA #RareDisease
1
9
1,840
Mark your calendar! 📅 FDA's virtual #RareDiseaseDay is February 23, 2026. Together, we're prioritizing accelerating medical products for rare diseases and ensuring patient perspectives guide our decisions. Every rare disease matters. Register now: fda.gov/rarediseaseday #FDA #RareDisease
8
622
$VKTX New Chief Commercial Officer (CCO) Neil Aubuchon Career Highlights (courtesy @tigeroflebanon on StockTwits and @vtcarguy81 on X): • Key member of the marketing team responsible for the U.S. product launch of Actos - achieved $1 billion in annual revenue. • Took a declining product after significant negative press to #1 in the market place • Responsibility for the successful launch of new products, Forteo, Cymbalta, and Strattera • Lead Team member responsible for running Lilly Bio-Medicines – Lilly’s largest global Business Unit ($10B+) • Lead the largest commercial organization ($1B+, 1000+ employees) within Eli Lilly Japan, including P&L responsibility • Head of Global Marketing, part of key C-Suite executive committees • Led the Amgen global commercialization agreement negotiations with Astra-Zeneca for Tezspire • Responsible for commercial strategy at AbCellera across the portfolio of clinical and preclinical programs “Buckle up Boys. He’s got a hell of a lot more to work with here entering the biggest product market in history of biotech.”
5
1
37
2,791
$VKTX Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership roles across global commercial and marketing functions including focus within the cardiometabolic space. Neil is a perfect fit to lead our commercialization strategy for VK2735, including engagement with potential strategic partners, representing a key step in our preparation for commercial success," said Brian Lian, Ph.D., chief executive officer of Viking. finance.yahoo.com/news/vikin…
1
1
1
39
3,502
$VKTX As of January 2026, Viking Therapeutics (VKTX) remains a major contender in the global obesity drug market, advancing a competitive "dual-track" pipeline of both injectable and oral treatments. While currently in a pre-commercial phase, the company is positioned for a pivotal year characterized by late-stage clinical progress and potential partnership catalysts.  Clinical Pipeline Status (January 2026) •Injectable VK2735 (Phase 3): Viking’s lead asset, a dual GLP-1/GIP agonist, is currently in two Phase 3 trials—VANQUISH-1 (obesity) and VANQUISH-2(obesity with Type 2 diabetes). Enrollment for VANQUISH-1 was completed ahead of schedule on November 19, 2025, and VANQUISH-2 is expected to finish enrollment in Q1 2026. Interim data updates may occur late in 2026, with full data likely in late 2027. •Oral VK2735 (Phase 2/3 Transition): The oral formulation demonstrated "unmatched" weight loss of 12.2% in 13 weeks during Phase 2 trials. A Phase 3 trial is expected to launch later in 2026. Viking is also exploring oral dosing as a "maintenance" strategy to help patients sustain weight loss after initial injectable treatments. •Amylin Agonist Program: Viking is expanding its metabolic portfolio with a new amylin agonist program, with an Investigational New Drug (IND)application planned for Q1 2026.  Financial and Market Position •Strong Liquidity: Viking ended 2025 with approximately $714–$715 million in cash and short-term investments, providing a significant "war chest" to fund expensive Phase 3 trials through expected data readouts. •Takeover/Partnership Target: Due to its robust Phase 2 efficacy data and dual formulation strategy, analysts frequently cite Viking as a prime acquisition target for larger pharmaceutical companies as a potential commercialization partner. •Analyst Sentiment: Wall Street maintains a consensus "Strong Buy" on VKTX as of January 2026, with 16 out of 19 covering analysts rating it as such. Average price targets suggest over 140% upside from current levels.  2026 Key Catalyst Timeline 1Q1 2026: Completion of enrollment for the Phase 3 VANQUISH-2 trial. 2Q1 2026: Planned IND submission for the new amylin agonist program. 3 Q1 2026: During October 2025 earnings call Viking CEO announced a manuscript was accepted for publication in a "leading medical journal" which describes the results of its Phase 2 VENTURE oral dosing study of the drug candidate VK2735. The publication is expected in early 2026.  4 Mid-2026: Anticipated results from Phase 1/2 maintenance and transition dosing studies. 5 Late 2026: Potential interim Phase 3 data for injectable VK2735 and start of Phase 3 for the oral
2
1
1
31
3,405
$VKTX VKTX Deep Dive: VK2735 (Oral 12.2% in 13 Weeks) + Phase 3 VANQUISH, $714.6M Cash — Analyst Targets up to $125 (Sources Linked) merlintrader.com/vktx-viking…
1
1
6
717